Maravai Lifesciences Holdings, Inc. Stock Price, News & Analysis

Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.

The report details strong employee engagement with a 95% survey participation rate and expanded employee resource initiatives. In governance, the company appointed R. Andrew Eckert as independent Chairman and strengthened its intellectual property position. Sustainability efforts included enhanced greenhouse gas emissions reporting, solar energy generation at the Leland facility, and EV charging stations that saved over 19,000 gallons of gasoline.

TriLink BioTechnologies (NASDAQ: MRVI) has launched its first mRNA synthesis kit featuring CleanCap® capping technology. The all-in-one in vitro transcription (IVT) kit delivers up to 2X more mRNA yield and up to 85% lower dsRNA compared to market alternatives. The kit includes CleanCap® AG (3′ OMe), CleanScribe™ RNA Polymerase, nucleotides with N1-methylpseuouridine, and CleanScript® IVT.

To celebrate the launch, TriLink is donating ten kits each to seven academic institutions across the U.S. and Europe, including Houston Methodist Research Institute, UC San Diego, University Medical Center Utrecht, University of Oxford, and Yale School of Medicine. The donated kits can yield up to a combined 250mg of capped mRNAs.

The kit features CleanCap AG (3′ OMe) with over 95% capping efficiency for improved protein expression, streamlining mRNA manufacturing with fewer steps compared to traditional ARCA or enzymatic methods.

TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has signed a Memorandum of Understanding (MOU) with the International Vaccine Institute (IVI) to advance mRNA-based vaccine development. The collaboration aims to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives, with a focus on improving access in low- and middle-income countries (LMICs).

TriLink's CleanCap® technology, launched in 2017, is currently used in most approved COVID-19 mRNA and saRNA vaccines. In 2024, the company expanded its offerings with IVT enzymes and opened a GMP manufacturing facility in San Diego. IVI, established in 1997 in Seoul, focuses on developing vaccines for diseases affecting LMICs, including cholera, typhoid, chikungunya, and COVID-19.

Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q1 2025 financial results with revenue of $46.9 million, down 27.0% year-over-year. The company posted a net loss of $(52.9) million, including a $12.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.5) million. The decline was primarily driven by the Nucleic Acid Production segment, which fell 37.5% to $28.8 million due to lack of high-volume CleanCap orders for commercial vaccine programs. Biologics Safety Testing revenue remained relatively flat at $18.1 million. Despite challenges, management maintained full-year 2025 revenue guidance of $185.0-205.0 million, citing solid execution in their base business which grew by $4 million compared to Q4 2024.

Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day.

Participants can join the conference call by dialing (800) 343-4849 or (203) 518-9848 and referencing Conference ID MARAVAI. The event will also be accessible via webcast through the "Investors" section of Maravai's website.

Maravai LifeSciences Holdings (NASDAQ:MRVI) faces a significant class action lawsuit following concerning financial disclosures. On February 25, 2025, the company announced delays in its earnings release and annual report, citing issues with revenue recognition and potential impairment charges. This announcement triggered a 21.7% drop in stock price.

The lawsuit, filed in the U.S. District Court for the Southern District of California, alleges that Maravai misled investors about its financial condition during the period between August 7, 2024, and February 24, 2025. Key allegations include undisclosed weaknesses in internal financial controls, improper revenue recording, inflated goodwill valuation, and misleading statements about growth prospects.

Affected investors who experienced financial losses have until May 5, 2025, to apply for lead plaintiff status in the legal proceedings.

Maravai LifeSciences (NASDAQ:MRVI) faces a significant class action lawsuit following troubling financial disclosures. On February 25, 2025, the company delayed its earnings release and annual report, triggering a 21.7% stock price decline.

The lawsuit, filed in the U.S. District Court for the Southern District of California, alleges that Maravai misled investors between August 7, 2024, and February 24, 2025. Key allegations include failure to disclose weak internal financial controls, improper revenue recognition, overstated goodwill valuation, and misleading statements about growth potential.

Affected investors who purchased MRVI shares during the specified period have until May 5, 2025, to seek lead plaintiff status. The case is being handled by Cohen Milstein, a firm noted for securing a $1 billion recovery in the Wells Fargo litigation in 2024.

Maravai LifeSciences (NASDAQ:MRVI) faces a securities class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit covers investors who purchased shares between August 7, 2024, and February 24, 2025, with a lead plaintiff deadline of May 5, 2025.

The legal action alleges violations of Securities Exchange Act Sections 10(b) and 20(a), claiming the company and senior executives misled investors about:

• Inadequate financial controls, especially in revenue recognition
• Incorrect revenue reporting for key transactions in fiscal 2024
• Overstated goodwill valuation
• Misrepresentation of financial condition and growth potential

On February 25, 2025, Maravai delayed its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge, resulting in a 21.7% stock price decline.

Maravai LifeSciences (NASDAQ:MRVI) faces a securities class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit covers investors who purchased shares between August 7, 2024, and February 24, 2025.

The complaint alleges that Maravai and senior executives made false and misleading statements regarding:

• Financial controls and revenue recognition policies
• Improper revenue recording in fiscal 2024
• Overstated goodwill valuation
• Misrepresented financial condition and growth prospects

On February 25, 2025, Maravai announced delays in its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge. The stock subsequently dropped 21.7%. Affected investors have until May 5, 2025, to file for lead plaintiff status in the case.